Sam Altman invested $180 million into a company trying to delay death | MIT Technology Review
technologyreview.com · 3,188 words · saved by 1 readers
Can anti-aging breakthroughs add 10 healthy years to the human lifespan? The CEO of OpenAI is paying to find out.
Sam Altman invested $180 million into a company trying to delay death | MIT Technology Review Skip to Content When a startup called Retro Biosciences eased out of stealth mode in mid-2022, it announced it had secured $180 million to bankroll an audacious mission: to add 10 years to the average human life span . It had set up its headquarters in a raw warehouse space near San Francisco just the year before, bolting shipping containers to the concrete floor to quickly make lab space for the scientists who had been enticed to join the company. Retro said that it would “prize speed” and “tighten f
related reading
- Sam Altman May Control Our Future—Can He Be Trusted? | The New Yorkernewyorker.com
- Meet Altos Labs, Silicon Valley's latest wild bet on living forever | MIT Technology Reviewtechnologyreview.com
- Sam Altman’s Manifest Destiny | The New Yorkernewyorker.com
- What Sam Altman Doesn't Want You To Knowyoutube.com
- OpenAI CEO Sam Altman | AI for the Next Erayoutube.com
- Sam Altman's leap of faith | TechCrunchtechcrunch.com
- Sam Altman - Wikipediaen.wikipedia.org
- Sam Altman, Co-Founder and CEO of OpenAI: Staying Human While Scaling Superintelligenceyoutube.com
- Amazon to invest up to $4 billion in Anthropic AI. What to know about the startup. | Voxvox.com
- David Senra: Sam Altman on Building OpenAI & Betting on the Impossibledavidsenra.com
- Inside OpenAI’s Reboottime.com
- Sam Altman: The Success Equation - Play For Thoughtsplayforthoughts.com